Design, synthesis and biological evaluation of some isatin-linked chalcones as novel anti-breast cancer agents: A molecular hybridization approach

Biomedicine and Preventive Nutrition

Volumn 3, Issue 4, 2013, Pages 325-330

  Karthikeyan, Chandrabose ^a   Solomon, Viswas Raja ^b,c   Lee, Hoyun ^b,c   Trivedi, Piyush ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b Northeastern Regional Cancer Centre   (Canada)

^c LAURENTIAN UNIVERSITY   (Canada)

Author keywords

Breast cancer; Chalcones; Isatins; Kinase inhibitors; SRB assay

Indexed keywords

3 (2 OXO 2 PARA TOLYLETHYLIDENE)INDOLIN 2 ONE; 3 (2 OXO 2 PHENYLETHYLIDENE)INDOLIN 2 ONE; 3 [2 (2 METHOXYPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (3 NITROPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (3,4 DIMETHOXYPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (4 BROMOROPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (4 CHLOROPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (4 FLUOROPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (4 METHOXYPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 3 [2 (4 NITROPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 5 BROMO 3 (2 OXO 2 PHENYLETHYLIDENE)INDOLIN 2 ONE; 5 CHLORO 3 (2 OXO 2 PHENYLETHYLIDENE)INDOLIN 2 ONE; 5 CHLORO 3 [2 (3,4 DIMETHOXYPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; 5 CHLORO 3 [2 (4 FLUOROPHENYL) 2 OXOETHYLIDENE]INDOLIN 2 ONE; CHALCONE DERIVATIVE; CISPLATIN; ISATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CELL STRAIN MDA MB231; CELL STRAIN MDA MB468; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR HYBRIDIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

MAMMALIA;

EID: 84889607217     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2013.04.001     Document Type: Article

References (31)

1. Shankar R., Chakravarti B., Singh U.S., Ansari M.I., Deshpande S., Dwivedi S.K., et al. Synthesis and biological evaluation of 3,4,6-triaryl-2-pyranones as a potential new class of anti-breast cancer agents. Bioorg Med Chem 2009, 17:3847-3856.
2. Das J.R., Fryar-Tita E.B., Zhou Y., Green S., Southerland W.M., Bowen D. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res 2007, 27:3791-3799.
3. Solomon V.R., Lee H. Anti-breast cancer activity of heteroaryl chalcone derivatives. Biomed Pharmacother 2012, 66:213-220.
4. Viegas-Junior C., Danuello A., da Silva Bolzani V., Barreiro E.J., Fraga C.A. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007, 14:1829-1852.
5. Walsh J.J., Bell A. Hybrid drugs for malaria. Curr Pharm Des 2009, 15:2970-2985.
6. Anand N., Singh P., Sharma A., Tiwari S., Singh V., Singh D.K., et al. Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG. Bioorg Med Chem 2012, 20:5150-5163.
7. Guantai E.M., Ncokazi K., Egan T.J., Gut J., Rosenthal P.J., Smith P.J., et al. Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds. Bioorg Med Chem 2010, 18:8243-8256.
8. Medvedev A., Buneeva O., Glover V. Biological targets for isatin and its analogues: implications for therapy. Biologics: Targets & Therapy 2007, 1:151-162.
9. Vine K.L., Matesic L., Locke J.M., Ranson M., Skropeta D. Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem 2009, 9:397-414.
10. Bauer D.J., Sadler P.W. The structure-activity relationships of the antiviral chemotherapeutic activity of isatin beta-thiosemicarbazone. Br J Pharmacol Chemother 1960, 15:101-110.
11. Sriram D., Bal T.R., Yogeeswari P. Synthesis, antiviral and antibacterial activities of Isatin Mannich bases. Med Chem Res 2005, 14:211-228.
12. Sriram D., Yogeeswari P., Meena K. Synthesis, anti-HIV and antitubercular activities of isatin derivatives. Pharmazie 2006, 61:274-277.
13. Atta-Ur-Rehman, Ijaz A.S., Choudhary M.I., Amtul Z., Atta-Ur-Rahman New isatin derivatives and their antimicrobial activity. J Chem Soc Pak 1997, 19:230-236.
14. Verma M., Pandeya S.N., Singh K.N., Stables J.P. Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharm 2004, 54:49-56.
15. Woodard C.L., Li Z., Kathcart A.K., Terrell J., Gerena L., Lopez-Sanchez M., et al. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin-dependent protein kinases. J Med Chem 2003, 46:3877-3882.
16. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
17. Prenen H., Cools J., Mentens N., Folens C., Sciot R., Schöffski P., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006, 12:2622-2627.
18. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999, 1:60-67.
19. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., et al. Indirubin derivatives inhibit STAT3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005, 102:5998-6003.
20. Chu W., Rothfuss J., Zhou D., Mach R.H. Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay. Bioorg Med Chem Lett 2011, 21:2192-2197.
21. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007, 42:125-137.
22. Ni L., Meng C.Q., Sikorski J.A. Recent advances in therapeutic chalcones. Expert Opin Ther Pat 2004, 14:1669-1691.
23. Juvale K., Pape V.F., Wiese M. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg Med Chem 2012, 20:346-355.
24. Kamal A., Reddy J.S., Ramaiah M.J., Dastagiri D., Bharathi E.V., Prem Sagar M.V., et al. Synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents. Med Chem Commun 2010, 1:355-360.
25. Sharma A., Chakravarti B., Gupt M.P., Siddiqui J.A., Konwar R., Tripathi R.P. Synthesis and anti-breast cancer activity of biphenyl based chalcones. Bioorg Med Chem 2010, 18:4711-4720.
26. Patel K., Karthikeyan C., Solomon V.R., Moorthy N.S.H.N., Lee H., Sahu K., et al. Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines. Lett Drug Des Discov 2011, 8:308-311.
27. Azizian J., Shaabanzadeh M., Hatamjafari F., Mohammadizadeh M.R. One pot rapid and efficient synthesis of new spiro derivatives of 11H-indeno[1,2-b]quinoxalin-11-one, 6H-indeno[1,2-b]pyrido [3,2-e]pyrazin-6-one and isatin-based 2-pyrazolines. ARKIVOC 2006, XI:47-58.
28. Solomon V.R., Hu C., Lee H. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg Med Chem 2009, 17:7585-7592.
29. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990, 82:1107-1112.
30. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
31. Giraud F., Alves G., Debiton E., Nauton L., Théry V., Durieu E., et al. Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. J Med Chem 2011, 54:4474-4489.